Dr Jennifer Woyach speaks to ecancer at ASH 2018 about treatments for older adults with chronic lymphocytic leukaemia (CLL).
She explains that the Phase III trial that aimed to discover whether targeted therapy with the bruton’s tyrosine kinase (BTK) inhibitor ibrutinib is better than current standard of care, and whether the addition of rituximab improved its efficacy over ibrutinib alone.
She also comments on the practice changing potential of the trial for older patients.
Dr Woyach concludes that there has been a significantly improved progression free survival for patients treated on either of the ibrutinib arms.
Watch Dr Woyach's press conference here.
Read the article about this work here.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.